Skip to content

Price / book at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
6.2×-1.0×
Eli Lilly logo
Eli LillyLLY
26.3×-20.7×
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
316.5×+303×
Prime Medicine logo
Prime MedicinePRME
8.2×+5.8×
Wave Life Sciences logo
Wave Life SciencesWVE
2.7×-4.6×
Perspective Therapeutics logo
Perspective TherapeuticsCATX
1.4×+0.8×

Other financials

Income statement

See full
Revenue-
Operating income-$5.2M-62.2%
Net income-$3.9M-48.3%
EPS (diluted)-$0.19

Balance sheet

See full
Cash & equivalents$52.5M+32.3%
Total debt$230.4K+2,692%
Total equity$135.4M+153%
Total assets$138.0M+150%

Cash flow

See full
Operating cash flow-$3.5M+38.7%

Valuation

See full
Market cap$587.04M+192%
Enterprise value$534.72M+232%

Returns & leverage

See full
Return on equity-15.9%-6.6pp
Debt / equity0.0×
Current ratio56×

Where this comes from

Calculated from Monopar Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monopar Therapeutics's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Monopar Therapeutics's price / book?
Monopar Therapeutics (MNPR) reported price / book of 2.7× in Q1 2026.
How has Monopar Therapeutics's price / book changed year-over-year?
Monopar Therapeutics's price / book decreased by 34.7% year-over-year, from 4.1× to 2.7×.
What is the long-term trend for Monopar Therapeutics's price / book?
Over 5 years (2020 to 2025), Monopar Therapeutics's price / book has grown at a -33.6% compound annual growth rate (CAGR), from 24.6× to 3.2×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.